Has Nirmala Shevde, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,151 in general payments to Nirmala Shevde, MD across 46 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nirmala Shevde, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nirmala Shevde, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nirmala Shevde, MD

Hematology-Oncology · New Hyde Park, NYNPI 1740365832

Payments from drug & device makers

What this record shows

This record is dominated by other: $2,062 of the $3,151 with a category attached, or 65.5%. Novartis accounts for 74.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $1,169, 2.2 times the $534 reported in 2019.

$3,151in general payments, 2019–2025

Across 46 payments — averaging $68.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2K
Lilly USA, LLC$239
GSK$172
Stemline Therapeutics Inc.$125
Pfizer$123
Merck$99
plus $56 from 3 others

What the payments were for

Food & beverage$83827%
Education$2508%
Other$2,06265%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	35	$2,337
Lilly USA, LLC	2	$239
GSK	3	$172
Stemline Therapeutics Inc.	1	$125
Pfizer	1	$123
Merck	1	$99
Sanofi	1	$29
Covidien LP	1	$16
Gilead	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,151 in reported general payments places this provider in the 85th percentile of 38 hematology-oncology providers in New York.

See all hematology-oncology providers in New York →

Medicare billing

Part B allowed, 2024

$461,868

Medicare patients

208

Services billed

25,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	156	$2,850
Exemestane	16	$2,402
Letrozole	35	$731
Alendronate Sodium	18	$156

Paid to pharmacies, not to this prescriber.

Other hematology-oncology in New Hyde Park

Klaus DittmarNew Hyde Park$0
Hina NaqviNew Hyde Park$0
Amy SharmaBronx$11K
Anna UrazovBrooklyn$5K
Sherry HsuNew York$4K
Xuan GeBronx$4K
Ioannis MantzarisBronx$3K
Rana DouliRego Park$2K
Neha MaithelBrooklyn$1K
Anneyamma MannancherilWhite Plains$969

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →